Combining Immune Checkpoint and VEGFR Inhibition in Favorable Risk and Elderly Patients With Metastatic Renal Cell Carcinoma

scientific article published on 05 December 2019

Combining Immune Checkpoint and VEGFR Inhibition in Favorable Risk and Elderly Patients With Metastatic Renal Cell Carcinoma is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1016/J.CLGC.2019.11.016
P698PubMed publication ID32144046

P2093author name stringDavid F McDermott
Roger B Davis
Wenxin Xu
Brian Healy
Andreas Varkaris
P2860cites workPhase I trial of sunitinib malate plus interferon-alpha for patients with metastatic renal cell carcinomaQ33383270
Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survivalQ34021957
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.Q52644831
Phase II trial of sorafenib plus interferon alfa-2b as first- or second-line therapy in patients with metastatic renal cell cancer.Q53470792
A phase II study of bevacizumab and high-dose interleukin-2 in patients with metastatic renal cell carcinoma: a Cytokine Working Group (CWG) study.Q54718176
Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell CarcinomaQ62514960
Choosing Front-line Treatment for Metastatic Renal Cancer: Which Data Are Meaningful?Q88865246
Elderly patients with metastatic renal cell carcinoma: position paper from the International Society of Geriatric OncologyQ89074133
Radical shifts in the first-line management of metastatic renal cell carcinomaQ90412378
Lenvatinib plus everolimus or pembrolizumab versus sunitinib in advanced renal cell carcinoma: study design and rationaleQ91249826
A Joint Statement from the European Association of Urology Renal Cell Cancer Guidelines Panel and the International Kidney Cancer Coalition: The Rejection of Ipilimumab and Nivolumab for Renal Cancer by the Committee for Medicinal Products for HumanQ91368102
Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell CarcinomaQ91700806
European Association of Urology Guidelines on Renal Cell Carcinoma: The 2019 UpdateQ91900774
NCCN Guidelines Updates: Management of Metastatic Kidney CancerQ92217897
Sequencing and Combination of Systemic Therapy in Metastatic Renal Cell CarcinomaQ92386877
Safety and Efficacy of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Disease: A Nationwide, Multicenter Cohort StudyQ92399771
Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibition Is the New Backbone in First-line Treatment of Metastatic Clear-cell Renal Cell CarcinomaQ92448726
Immunotherapy for renal cell carcinomaQ92584185
The Changing Therapeutic Landscape of Metastatic Renal CancerQ92826118
First-line Immuno-Oncology Combination Therapies in Metastatic Renal-cell Carcinoma: Results from the International Metastatic Renal-cell Carcinoma Database ConsortiumQ92844547
Towards individualized therapy for metastatic renal cell carcinomaQ93139113
Emerging Role of Combination Immunotherapy in the First-line Treatment of Advanced Renal Cell Carcinoma: A ReviewQ93375175
P921main subjectrenal cell carcinomaQ1164529
metastatic renal cell carcinomaQ19000948
P577publication date2019-12-05
P1433published inClinical Genitourinary CancerQ332266
P1476titleCombining Immune Checkpoint and VEGFR Inhibition in Favorable Risk and Elderly Patients With Metastatic Renal Cell Carcinoma

Search more.